These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 22759068)

  • 1. Isolation and functional characterization of peptide agonists of PTPRJ, a tyrosine phosphatase receptor endowed with tumor suppressor activity.
    Paduano F; Ortuso F; Campiglia P; Raso C; Iaccino E; Gaspari M; Gaudio E; Mangone G; Carotenuto A; Bilotta A; Narciso D; Palmieri C; Agosti V; Artese A; Gomez-Monterrey I; Sala M; Cuda G; Iuliano R; Perrotti N; Scala G; Viglietto G; Alcaro S; Croce CM; Novellino E; Fusco A; Trapasso F
    ACS Chem Biol; 2012 Oct; 7(10):1666-76. PubMed ID: 22759068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of PTPRJ agonist peptides that effectively inhibit in vitro cancer cell proliferation and tube formation.
    Ortuso F; Paduano F; Carotenuto A; Gomez-Monterrey I; Bilotta A; Gaudio E; Sala M; Artese A; Vernieri E; Dattilo V; Iuliano R; Brancaccio D; Bertamino A; Musella S; Alcaro S; Grieco P; Perrotti N; Croce CM; Novellino E; Fusco A; Campiglia P; Trapasso F
    ACS Chem Biol; 2013 Jul; 8(7):1497-506. PubMed ID: 23627474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The activation of the phosphotyrosine phosphatase eta (r-PTP eta) is responsible for the somatostatin inhibition of PC Cl3 thyroid cell proliferation.
    Florio T; Arena S; Thellung S; Iuliano R; Corsaro A; Massa A; Pattarozzi A; Bajetto A; Trapasso F; Fusco A; Schettini G
    Mol Endocrinol; 2001 Oct; 15(10):1838-52. PubMed ID: 11579215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein tyrosine phosphatase PTPRJ is negatively regulated by microRNA-328.
    Paduano F; Dattilo V; Narciso D; Bilotta A; Gaudio E; Menniti M; Agosti V; Palmieri C; Perrotti N; Fusco A; Trapasso F; Iuliano R
    FEBS J; 2013 Jan; 280(2):401-12. PubMed ID: 22564856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel splice variant of the protein tyrosine phosphatase PTPRJ that encodes for a soluble protein involved in angiogenesis.
    Bilotta A; Dattilo V; D'Agostino S; Belviso S; Scalise S; Bilotta M; Gaudio E; Paduano F; Perrotti N; Florio T; Fusco A; Iuliano R; Trapasso F
    Oncotarget; 2017 Feb; 8(6):10091-10102. PubMed ID: 28052032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, Synthesis, Biological Activity, and Structural Analysis of Lactam-Constrained PTPRJ Agonist Peptides.
    Sala M; Spensiero A; Scala MC; Pepe G; Bilotta A; Paduano F; D'Agostino S; Lanzillotta D; Bertamino A; Novellino E; Trapasso F; Gomez-Monterrey IM; Campiglia P
    ChemMedChem; 2018 Aug; 13(16):1673-1680. PubMed ID: 29888867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphorylation of DEP-1/PTPRJ on threonine 1318 regulates Src activation and endothelial cell permeability induced by vascular endothelial growth factor.
    Spring K; Lapointe L; Caron C; Langlois S; Royal I
    Cell Signal; 2014 Jun; 26(6):1283-93. PubMed ID: 24583284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulated expression of PTPRJ by COX-2/PGE2 axis in endothelial cells.
    Xu X; Lan W; Jin X; Wang B; Yan H; Chen X; Lai X; Zhang L; Zhang X; Li Z
    PLoS One; 2014; 9(12):e114996. PubMed ID: 25532119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The receptor protein tyrosine phosphatase PTPRJ negatively modulates the CD98hc oncoprotein in lung cancer cells.
    D'Agostino S; Lanzillotta D; Varano M; Botta C; Baldrini A; Bilotta A; Scalise S; Dattilo V; Amato R; Gaudio E; Paduano F; Palmieri C; Iuliano R; Perrotti N; Indiveri C; Fusco A; Gaspari M; Trapasso F
    Oncotarget; 2018 May; 9(34):23334-23348. PubMed ID: 29805737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The eighth fibronectin type III domain of protein tyrosine phosphatase receptor J influences the formation of protein complexes and cell localization.
    Iuliano R; Raso C; Quintiero A; Pera IL; Pichiorri F; Palumbo T; Palmieri D; Pattarozzi A; Florio T; Viglietto G; Trapasso F; Croce CM; Fusco A
    J Biochem; 2009 Mar; 145(3):377-85. PubMed ID: 19122201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adenovirus-mediated overexpression and stimulation of the human angiotensin II type 2 receptor in porcine cardiac fibroblasts does not modulate proliferation, collagen I mRNA expression and ERK1/ERK2 activity, but inhibits protein tyrosine phosphatases.
    Warnecke C; Kaup D; Marienfeld U; Poller W; Yankah C; Gräfe M; Fleck E; Regitz-Zagrosek V
    J Mol Med (Berl); 2001 Sep; 79(9):510-21. PubMed ID: 11692164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-resolution loss of heterozygosity screening implicates PTPRJ as a potential tumor suppressor gene that affects susceptibility to Non-Hodgkin's lymphoma.
    Aya-Bonilla C; Green MR; Camilleri E; Benton M; Keane C; Marlton P; Lea R; Gandhi MK; Griffiths LR
    Genes Chromosomes Cancer; 2013 May; 52(5):467-79. PubMed ID: 23341091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1.
    Kortylewski M; Heinrich PC; Mackiewicz A; Schniertshauer U; Klingmüller U; Nakajima K; Hirano T; Horn F; Behrmann I
    Oncogene; 1999 Jun; 18(25):3742-53. PubMed ID: 10391682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel cyclinE/cyclinA-CDK inhibitor targets p27(Kip1) degradation, cell cycle progression and cell survival: implications in cancer therapy.
    Dai L; Liu Y; Liu J; Wen X; Xu Z; Wang Z; Sun H; Tang S; Maguire AR; Quan J; Zhang H; Ye T
    Cancer Lett; 2013 Jun; 333(1):103-12. PubMed ID: 23354589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients.
    Daneshmand M; Parolin DA; Hirte HW; Major P; Goss G; Stewart D; Batist G; Miller WH; Matthews S; Seymour L; Lorimer IA
    Clin Cancer Res; 2003 Jul; 9(7):2457-64. PubMed ID: 12855618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endothelium-derived nitric oxide (NO) activates the NO-epidermal growth factor receptor-mediated signaling pathway in bradykinin-stimulated angiogenesis.
    Moraes MS; Costa PE; Batista WL; Paschoalin T; Curcio MF; Borges RE; Taha MO; Fonseca FV; Stern A; Monteiro HP
    Arch Biochem Biophys; 2014 Sep; 558():14-27. PubMed ID: 24960080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disrupting the transmembrane domain-mediated oligomerization of protein tyrosine phosphatase receptor J inhibits EGFR-driven cancer cell phenotypes.
    Bloch E; Sikorski EL; Pontoriero D; Day EK; Berger BW; Lazzara MJ; Thévenin D
    J Biol Chem; 2019 Dec; 294(49):18796-18806. PubMed ID: 31676686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor.
    Wang D; Tang F; Wang S; Jiang Z; Zhang L
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):173-83. PubMed ID: 21638122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Function and regulatory mechanisms of the candidate tumor suppressor receptor protein tyrosine phosphatase gamma (PTPRG) in breast cancer cells.
    Shu ST; Sugimoto Y; Liu S; Chang HL; Ye W; Wang LS; Huang YW; Yan P; Lin YC
    Anticancer Res; 2010 Jun; 30(6):1937-46. PubMed ID: 20651337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic ablation of Ptprj, a mouse cancer susceptibility gene, results in normal growth and development and does not predispose to spontaneous tumorigenesis.
    Trapasso F; Drusco A; Costinean S; Alder H; Aqeilan RI; Iuliano R; Gaudio E; Raso C; Zanesi N; Croce CM; Fusco A
    DNA Cell Biol; 2006 Jun; 25(6):376-82. PubMed ID: 16792508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.